Researchers trained machine learning (ML) models to analyze RNA molecular signatures in patients’ blood.
Q&A: A biotech VC leader shares her next big bets
Kristina Burow has a well-trained eye. That’s true of her work at ARCH Venture Partners, one of the drug industry’s largest and most active investment